| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Immunobiology Program, Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05405; and Institute of Biochemistry, University of Lausanne, BIL Biomedical Research Center, Epalinges, Switzerland
Caspase activity is required not only for the death of T cells, but also for their activation. A delicate balance of caspase activity is thus required during T cell activation at a level that will not drive cell death. How caspase activity is initiated and regulated during T cell activation is not known. One logical candidate for this process is cellular FLIP long form (c-FLIPL), because it can block caspase-8 recruitment after Fas (CD95) ligation as well as directly heterodimerize with and activate caspase-8. The current findings demonstrate that after T cell activation, caspase-8 and c-FLIPL associate in a complex enriched for active caspases. This occurs coincidently with the cleavage of two known caspase-8 substrates, c-FLIPL and receptor interacting protein 1. Caspase activity is higher in wild-type CD8+ than CD4+ effector T cells. Increased expression of c-FLIPL results in augmented caspase activity in resting and effector T cells to levels that provoke cell death, especially of the CD8 subset. c-FLIPL is thus not only an inhibitor of cell death by Fas, it can also act as a principal activator of caspases independently of Fas.
This article has been cited by other articles:
|
|
 |
|
  N. Ueffing, M. Schuster, E. Keil, K. Schulze-Osthoff, and I. Schmitz Up-regulation of c-FLIPshort by NFAT contributes to apoptosis resistance of short-term activated T cells Blood, August 1, 2008; 112(3): 690 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Misra, J. Q. Russell, A. Koenig, J. A. Hinshaw-Makepeace, R. Wen, D. Wang, H. Huo, D. R. Littman, U. Ferch, J. Ruland, et al. Caspase-8 and c-FLIPL Associate in Lipid Rafts with NF-{kappa}B Adaptors during T Cell Activation J. Biol. Chem., July 6, 2007; 282(27): 19365 - 19374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Taoufik, S. Valable, G. J. Muller, M. L. Roberts, D. Divoux, A. Tinel, A. Voulgari-Kokota, V. Tseveleki, F. Altruda, H. Lassmann, et al. FLIPL Protects Neurons against In Vivo Ischemia and In Vitro Glucose Deprivation-Induced Cell Death J. Neurosci., June 20, 2007; 27(25): 6633 - 6646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Charo and P. F. Robbins Contrasting effects of FLIPL overexpression in human T cells on activation-induced cell death and cytokine production J. Leukoc. Biol., May 1, 2007; 81(5): 1297 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Rautajoki, E. M. Marttila, T. A. Nyman, and R. Lahesmaa Interleukin-4 Inhibits Caspase-3 by Regulating Several Proteins in the Fas Pathway during Initial Stages of Human T Helper 2 Cell Differentiation Mol. Cell. Proteomics, February 1, 2007; 6(2): 238 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zeuner, F. Pedini, M. Signore, G. Ruscio, C. Messina, A. Tafuri, G. Girelli, C. Peschle, and R. De Maria Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells Blood, May 1, 2006; 107(9): 3495 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wu, R. S. Misra, J. Q. Russell, R. A. Flavell, M. Rincon, and R. C. Budd Proteolytic Regulation of Nuclear Factor of Activated T (NFAT) c2 Cells and NFAT Activity by Caspase-3 J. Biol. Chem., April 21, 2006; 281(16): 10682 - 10690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Arechiga, B. D. Bell, J. C. Solomon, I. H. Chu, C. L. Dubois, B. E. Hall, T. C. George, D. M. Coder, and C. M. Walsh Cutting Edge: FADD Is Not Required for Antigen Receptor-Mediated NF-{kappa}B Activation J. Immunol., December 15, 2005; 175(12): 7800 - 7804. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
